BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15761193)

  • 1. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
    Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus.
    Schäfer A; Fraccarollo D; Vogt C; Flierl U; Hemberger M; Tas P; Ertl G; Bauersachs J
    Biochem Pharmacol; 2007 May; 73(9):1367-75. PubMed ID: 17270148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.
    Schäfer A; Fraccarollo D; Werner L; Bauersachs J
    Pharmacol Res; 2010 Nov; 62(5):432-8. PubMed ID: 20600916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer.
    Schäfer A; Fraccarollo D; Widder J; Eigenthaler M; Ertl G; Bauersachs J
    Eur J Heart Fail; 2009 Apr; 11(4):336-41. PubMed ID: 19193626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure.
    Schäfer A; Fraccarollo D; Pförtsch S; Loch E; Neuser J; Vogt C; Bauersachs J
    Basic Res Cardiol; 2011 May; 106(3):485-94. PubMed ID: 21287353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo.
    Schäfer A; Alp NJ; Cai S; Lygate CA; Neubauer S; Eigenthaler M; Bauersachs J; Channon KM
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1720-6. PubMed ID: 15242858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced basal nitric oxide bioavailability and platelet activation in young spontaneously hypertensive rats.
    Schäfer A; Widder J; Eigenthaler M; Ertl G; Bauersachs J
    Biochem Pharmacol; 2004 Jun; 67(12):2273-9. PubMed ID: 15163558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.
    Linz W; Itter G; Dobrucki LW; Malinski T; Wiemer G
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):180-5. PubMed ID: 14608524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
    Landsberger M; Jantzen F; Könemann S; Felix SB
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus.
    Schäfer A; Flierl U; Vogt C; Menninger S; Tas P; Ertl G; Bauersachs J
    Pharmacol Res; 2007 Sep; 56(3):217-23. PubMed ID: 17669665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent.
    Widder J; Behr T; Fraccarollo D; Hu K; Galuppo P; Tas P; Angermann CE; Ertl G; Bauersachs J
    Cardiovasc Res; 2004 Jul; 63(1):161-7. PubMed ID: 15194473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
    Schäfer A; Fraccarollo D; Hildemann S; Christ M; Eigenthaler M; Kobsar A; Walter U; Bauersachs J
    Thromb Haemost; 2003 Jun; 89(6):1024-30. PubMed ID: 12783115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
    Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
    J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes.
    Miersch S; Sliskovic I; Raturi A; Mutus B
    Free Radic Biol Med; 2007 Jan; 42(2):270-9. PubMed ID: 17189832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
    Stalker TJ; Lefer AM; Scalia R
    Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
    Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
    J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation.
    Pignatelli P; Carnevale R; Di Santo S; Bartimoccia S; Nocella C; Vicario T; Loffredo L; Angelico F; Violi F
    Biochem Pharmacol; 2012 Dec; 84(12):1635-42. PubMed ID: 23022230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
    Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
    J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
    Sicard P; Lauzier B; Oudot A; Busseuil D; Collin B; Duvillard L; Moreau D; Vergely C; Rochette L
    Arch Mal Coeur Vaiss; 2005; 98(7-8):804-8. PubMed ID: 16220751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.